Editas stock price target

Raymond James decreased their target price on shares of Editas Medicine from $44.00 to $41.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Finally, Chardan Capital restated a “buy” rating and set a $55.00 target price on shares of Editas Medicine in a research report on Wednesday, March 4th. Editas Medicine: Another Undervalued CRISPR Gene Editing ...

EDIT - Editas Medicine Inc Stock quote - CNNMoney.com Find real-time EDIT - Editas Medicine Inc stock quotes, company profile, news and forecasts from CNN Business. EDIT - Editas Medicine Inc Stock quote - CNNMoney.com Markets Editas Medicine - EDIT - Stock Price & News | The Motley Fool Real time Editas Medicine (EDIT) stock price quote, stock graph, news & analysis. Real time Editas Medicine (EDIT) stock price quote, stock graph, news & … Better Buy: Editas Medicine or Sangamo Therapeutics? | The ... Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and … EDIT | Editas Medicine Inc. Analyst Estimates & Rating – WSJ

Mar 19, 2020 · The Healthcare company has also assigned a $28 price target. Wells Fargo wasn’t the only research firm that published a report of Editas Medicine Inc., with other equities research analysts also giving their opinion on the stock. The stock had earned Neutral rating from Guggenheim Markets when it published its report on October 10, 2018.

The 7 analysts offering 12-month price forecasts for Editas Medicine Inc have a The current consensus among 10 polled investment analysts is to Hold stock in  Based on 7 analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $36.80 with a high forecast of $55.00  NASDAQ:EDITEditas Medicine Price Target & Analyst Ratings Their average twelve-month price target is $38.25, suggesting that the stock has a possible  7 equities research analysts have issued 1 year price targets for Editas Medicine's shares. Their forecasts range from $28.00 to $55.00. On average, they  

The 7 analysts offering 12-month price forecasts for Editas Medicine Inc have a The current consensus among 10 polled investment analysts is to Hold stock in 

Find real-time EDIT - Editas Medicine Inc stock quotes, company profile, news and forecasts from CNN Business. EDIT - Editas Medicine Inc Stock quote - CNNMoney.com Markets Editas Medicine - EDIT - Stock Price & News | The Motley Fool Real time Editas Medicine (EDIT) stock price quote, stock graph, news & analysis. Real time Editas Medicine (EDIT) stock price quote, stock graph, news & … Better Buy: Editas Medicine or Sangamo Therapeutics? | The ...

Created with Highstock 6.2.0 Number of Analysts BUY OUTPERFORM HOLD UNDERPERFORM SELL Oct 18 Nov 18 Dec 18 Jan 19 Feb 19 Mar 19 Apr 19 May 

Raymond James decreased their target price on shares of Editas Medicine from $44.00 to $41.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Finally, Chardan Capital restated a “buy” rating and set a $55.00 target price on shares of Editas Medicine in a research report on Wednesday, March 4th. Editas Medicine: Another Undervalued CRISPR Gene Editing ... Oct 24, 2016 · Editas Medicine is one of three publicly traded CRISPR/Cas9 gene editing companies with intellectual property licensed from Broad Institute/Harvard.The company's stock price has declined in recent mon Oppenheimer Reaffirms Their Hold Rating on Editas Medicine ... The word on The Street in general, suggests a Hold analyst consensus rating for Editas Medicine with a $38.00 average price target, a 69.1% upside from current levels. In a report issued on February 21, Wells Fargo also initiated coverage with a Hold rating on the stock with a …

Find real-time EDIT - Editas Medicine Inc stock quotes, company profile, news and forecasts from CNN Business. EDIT - Editas Medicine Inc Stock quote - CNNMoney.com Markets

Real time Editas Medicine (EDIT) stock price quote, stock graph, news & analysis . Editas Medicine Misses Revenue, Earnings Targets for Q4. Mark Prvulovic  It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company  EDIT | Complete Editas Medicine Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Real-time trade and investing ideas on Editas Medicine Inc. EDIT from the largest $EDIT NEW ARTICLE : Analysts Revise Estimates for Aurora Cannabis in 

Analysts Turn Mixed On Editas Medicine Inc. (NASDAQ:EDIT ...